Zango Wendé-Waoga Guillaume, Durieux Marie-Fleur, Faucher Jean-François
Faculté de pharmacie de Limoges, Limoges, France.
Laboratoire de parasitologie-mycologie, centre de biologie et de recherche en santé, CHU de Limoges, Limoges, France.
Rev Prat. 2022 Dec;72(10):1133-1129.
First malaria vaccine recommended by who. RST,S/AS01, the first WHO recommended vaccine against malaria, is the result of decades of research. It is a recombinant protein vaccine which induces a protection against Plasmodium falciparum malaria, mediated by both humoral, and cell mediated immune responses to the circumsporozoite protein. RST,S/AS01 is of moderate efficacy against malaria, but is an additional tool for malaria control and elimination. More effective vaccines against malaria are expected within the next decades. The WHO recommendation made in October 2021, of its widespread use in children in malaria-endemic areas has raised hopes but also concerns. The timeline of the adoption by most countries of moderate to high malaria transmission, of RST,S/AS01 in the small children vaccine schedule, is still unknown.
世卫组织推荐首款疟疾疫苗。RTS,S/AS01是世卫组织推荐的首款抗疟疾疫苗，是数十年研究的成果。它是一种重组蛋白疫苗，可诱导针对恶性疟原虫疟疾的保护作用，由针对环子孢子蛋白的体液免疫和细胞介导免疫反应介导。RTS,S/AS01对疟疾的疗效中等，但它是疟疾控制和消除的又一工具。预计未来几十年会有更有效的抗疟疾疫苗。2021年10月世卫组织建议在疟疾流行地区的儿童中广泛使用该疫苗，这带来了希望，但也引发了担忧。大多数疟疾传播程度为中度至高度的国家将RTS,S/AS01纳入幼儿疫苗接种计划的时间仍不确定
